-91%

est. 2Y upside i

HealthcareAI & MLSeed

Making cancer detection as easy as a pregnancy test

Rank

#2901

Sector

Biotech, Diagnostics, AI

Est. Liquidity

~8Y

Data Quality

Data: Low

Cleancard presents a high-risk, potentially high-reward equity opportunity.

Last updated: February 25, 2026

Bull (9%)+300%

Cleancard achieves early FDA breakthrough designation and successful initial clinical trial results for prostate and bladder cancer tests, leading to a significant Series B round at a $100M valuation. A major pharmaceutical or diagnostics company forms a strategic partnership, accelerating market entry and validation.

Base (48%)+75%

Cleancard makes steady progress on product development and secures initial regulatory approvals for a single cancer test. They raise a modest Series B round at a $43.75M valuation, demonstrating product viability but facing continued long development timelines and competitive pressures.

Bear (43%)-80%

Cleancard faces significant regulatory delays or challenges in clinical validation, or a dominant incumbent like Quest Diagnostics or Exact Sciences launches a competing at-home diagnostic with superior market reach. This leads to a down round or inability to raise further capital, resulting in an $5M valuation and significant loss of common stock value.

Est. time to liquidity~8.0 years

Preference Stack Risk

high

Investors hold $5M in liquidation preferences on an estimated $25M valuation, representing 20% of the company's value.

Dilution Risk

high

As a seed-stage company in a capital-intensive sector, Cleancard will require multiple significant funding rounds, leading to substantial future dilution for common shareholders.

Secondary Liquidity

none

Given its early stage and small employee base, there is currently no active secondary market or tender offers for Cleancard equity.

Other — 3 roles

View all 3 open roles at Cleancard →

Last updated: February 17, 2026

Questions to Ask at the Interview

Strategic questions based on Cleancard's data — designed to show you've done your homework.

  • 1

    “Given the high regulatory barriers and capital intensity in biotech diagnostics, what are Cleancard's key milestones for FDA approval over the next 24 months, and how are you mitigating the risk of delays?”

  • 2

    “With large incumbents like Quest Diagnostics and LabCorp, and even AI labs, potentially entering or expanding in the at-home diagnostics space, what is Cleancard's strategy to build and defend its competitive moat beyond its initial proprietary technology?”

  • 3

    “As an early-stage company, what is the anticipated funding roadmap beyond the current seed round, and how is the company planning to manage dilution for early employees as it raises subsequent, larger rounds?”

Community

Valuation Sentiment

Our model estimates -91% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.